Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 25 Jan 2023
Pricing of medicines in Switzerland | Three yearly price review: What are the most important changes for 2023?
24 January 2023 - The Federal Office of Public Health reviews the price of every medicinal product that is reimbursed under ...
Posted by Michael Wonder on 25 Jan 2023
UK to introduce first of its kind framework to make it easier to manufacture innovative medicines at the point of care
25 January 2023 - The establishment of a regulatory framework for point of care manufacturing would bring a range of benefits ...
Posted by Michael Wonder on 25 Jan 2023
NICE approves new migraine drug for NHS use in England and Wales
25 January 2023 - Drugs regulator recommends eptinezumab for adults when three previous treatments have failed. ...
Posted by Michael Wonder on 25 Jan 2023
US FDA approves ALK's Odactra (house dust mite allergen extract) tablet for sublingual use as immunotherapy for adolescents
25 January 2023 - Odactra is now indicated to treat house dust mite-induced allergic rhinitis, with or without conjunctivitis, in persons ...
Posted by Michael Wonder on 25 Jan 2023
The 4 biggest questions about the FDA’s forthcoming changes to accelerated approvals
25 January 2023 - Congress just boosted the FDA’s authority over the post-market clinical trials that are a condition of ...
Posted by Michael Wonder on 24 Jan 2023
Introducing RxPass from Amazon Pharmacy, a $5 prescription subscription that helps Prime members who take multiple medications save time and money
24 January 2023 - In addition to all the savings, convenience, and entertainment they already enjoy, Prime members can now receive ...
Posted by Michael Wonder on 24 Jan 2023
The FDA’s power to approve drugs faces sweeping challenge in lawsuit seeking to pull abortion pill from US market
24 January 2023 - Anti-abortion physicians are suing to overturn the FDA’s approval of mifepristone, which dates back more than two ...
Posted by Michael Wonder on 24 Jan 2023
HAS updates its recommendations for the proper use of osteoporosis drugs
24 January 2023 - Osteoporosis is a disease whose first cause is ageing and which is characterised by the reduction ...
Posted by Michael Wonder on 24 Jan 2023
Reform Medicare to sustain system
25 January 2023 - Australia’s hybrid public/private healthcare system, including the principle of universal coverage through Medicare, has served the nation ...
Posted by Michael Wonder on 24 Jan 2023
Sequential, multiple assignment, randomised trial designs
24 January 2023 - An adaptive intervention is a set of diagnostic, preventive, therapeutic, or engagement strategies that are used in ...
Posted by Michael Wonder on 24 Jan 2023
Fabre-Kramer Pharmaceuticals announces FDA acceptance of NDA resubmission as complete response and assignment of PDUFA regulatory action date
24 January 2023 - Submission of Exxua (gepirone hydrochloride), a novel targeted single serotonin receptor agonist for treatment of major ...
Posted by Michael Wonder on 24 Jan 2023
Verrica Pharmaceuticals announces resubmission of new drug application for VP-102 for the treatment of molluscum contagiosum
24 January 2023 - Potential first FDA approved therapy for treatment of molluscum contagiosum. ...
Posted by Michael Wonder on 24 Jan 2023
Private insurance can contribute to a healthier system
24 January 2023 - Given what many describe as a crisis in primary care, it’s well past time to revisit the ...
Posted by Michael Wonder on 23 Jan 2023
Conditional power: how likely is trial success?
23 January 2023 - Because of the costs and potential risks to participants, clinical trials should be initiated or continued only ...
Posted by Michael Wonder on 23 Jan 2023
Despite court ruling, FDA will continue with its approach to approving orphan drug exclusivity
23 January 2023 - In an unexpected move, the FDA will continue to apply exclusive marketing rights for so called ...